 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AMG 609 / Amgen
Trial completion: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jul 27, 2023
P1, N=47, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- || AMG 609 / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Apr 6, 2023
P1, N=47, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Jul 2023 | Trial primary completion date: May 2024 --> Jul 2023
- || AMG 609 / Amgen
Enrollment change, Trial completion date, Trial primary completion date: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 30, 2022
P1, N=56, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Jul 2023 | Trial primary completion date: May 2024 --> Jul 2023 N=106 --> 56 | Trial completion date: Nov 2023 --> May 2024 | Trial primary completion date: Nov 2023 --> May 2024
- || AMG 609 / Amgen
Trial completion date, Trial primary completion date: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 8, 2022
P1, N=106, Recruiting, Sponsor: Amgen
N=106 --> 56 | Trial completion date: Nov 2023 --> May 2024 | Trial primary completion date: Nov 2023 --> May 2024 Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: May 2023 --> Nov 2023
- || AMG 609 / Amgen
Trial completion date, Trial primary completion date: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Dec 27, 2021
P1, N=106, Recruiting, Sponsor: Amgen
Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: May 2023 --> Nov 2023 Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Dec 2022 --> May 2023
- ||| AMG 609 / Amgen
Enrollment open, Trial completion date, Trial primary completion date: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 24, 2021
P1, N=106, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Dec 2022 --> May 2023 Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
- ||| AMG 609 / Amgen
New P1 trial: Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Apr 23, 2021
P1, N=106, Not yet recruiting, Sponsor: Amgen